Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection

Journal of Surgical Oncology

Volumn 104, Issue 2, 2011, Pages 146-154

  Kondo, Naru ^a   Murakami, Yoshiaki ^a   Uemura, Kenichiro ^a   Sudo, Takeshi ^a   Hashimoto, Yasushi ^a   Nakashima, Akira ^a   Ohge, Hiroki ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

adjuvant chemotherapy; DPD; OPRT; pancreatic carcinoma; S 1; TS

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; TEGAFUR; THYMIDYLATE SYNTHASE;

EID: 79959948757     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21955     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Winter JM, Cameron JL, Campbell KA, et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-1210 (Discussion 1210-1191).
3. Shimada K, Sakamoto Y, Sano T, et al.: Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006; 139: 288-295.
4. Wagner M, Redaelli C, Lietz M, et al.: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-594. (Pubitemid 38624667)
5. Kuhlmann KF, de Castro SM, Wesseling JG, et al.: Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40: 549-558. (Pubitemid 38220772)
6. Traverso LW,: Pancreatic cancer: Surgery alone is not sufficient. Surg Endosc 2006; 20: S446-S449.
7. Kalser MH, Ellenberg SS,: Pancreatic cancer adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903. (Pubitemid 15040883)
8. Bakkevold KE, Arnesjo B, Dahl O, et al.: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698-703. (Pubitemid 23077048)
9. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782 (Discussion 782-774).
10. Kosuge T, Kiuchi T, Mukai K, et al.: A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006; 36: 159-165.
11. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210. (Pubitemid 38339364)
12. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-277. (Pubitemid 46143304)
13. Stocken DD, Buchler MW, Dervenis C, et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381. (Pubitemid 40705002)
14. Murakami Y, Uemura K, Sudo T, et al.: Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg 2008; 195: 757-762. (Pubitemid 351749450)
15. Murakami Y, Uemura K, Sudo T, et al.: Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma. J Gastrointest Surg 2008; 12: 534-541.
16. Murakami Y, Uemura K, Sudo T, et al.: Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg 2009; 13: 85-92.
17. Shirasaka T, Shimamato Y, Ohshimo H, et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557. (Pubitemid 26276346)
18. Fischel JL, Etienne MC, Spector T, et al.: Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation. Clin Cancer Res 1995; 1: 991-996.
19. Peters GJ, Laurensse E, Leyva A, et al.: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5â-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46: 20-28. (Pubitemid 16189022)
20. (UICC) International Union Against Cancer. TMN classification of malignant tumours. New York: Wiley-Liss; 2010.
21. Johnston PG, Fisher ER, Rockette HE, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-2647. (Pubitemid 24379651)
22. Nakayama S, Takeda S, Kawase Y, et al.: Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg 2004; 240: 840-844. (Pubitemid 39425777)
23. Kamoshida S, Shiogama K, Shimomura R, et al.: Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 2005; 14: 1223-1230.
24. Nakamura K, Yamaguchi T, Ishihara T, et al.: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 1575-1579. (Pubitemid 43924916)
25. Terashima M, Irinoda T, Fujiwara H, et al.: Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 2002; 22: 761-768. (Pubitemid 34475226)
26. Ichikawa W, Uetake H, Shirota Y, et al.: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9: 786-791. (Pubitemid 36182616)
27. Honda J, Sasa M, Moriya T, et al.: Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results. J Med Invest 2008; 55: 54-60. (Pubitemid 351643594)
28. Miyoshi T, Kondo K, Toba H, et al.: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur + uracil) in patients with non-small cell lung cancer. Anticancer Res 2007; 27: 2641-2648. (Pubitemid 47227977)
29. Tokunaga Y, Sasaki H, Saito T,: Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery 2007; 141: 346-353. (Pubitemid 46356434)
30. Kuramochi H, Hayashi K, Uchida K, et al.: High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol 2008; 63: 85-89.
31. Hu YC, Komorowski RA, Graewin S, et al.: Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003; 9: 4165-4171. (Pubitemid 37204035)
32. Nakagawa T, Tanaka F, Takata T, et al.: Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + uracil) in patients with p-stage I nonsmall-cell lung cancer. J Surg Oncol 2002; 81: 87-92.
33. Ichikawa W, Takahashi T, Suto K, et al.: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004; 91: 1245-1250. (Pubitemid 39424782)
34. Kikuchi M, Mikami T, Sato T, et al.: High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: Proposal of a logistic model for prediction. Br J Cancer 2009; 101: 116-123.
35. Harada K, Kawashima Y, Yoshida H, et al.: Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Oncol Rep 2006; 15: 1417-1423.
36. Fukui Y, Oka T, Nagayama S, et al.: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008; 22: 709-716.
37. Mori K, Hasegawa M, Nishida M, et al.: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000; 17: 33-38.
38. Giovannetti E, Del Tacca M, Mey V, et al.: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-3935.
39. Farrell JJ, Elsaleh H, Garcia M, et al.: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136: 187-195.